import streamlit as st
import google.generativeai as genai

# --- ğŸ¥ å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ± (2026 å°ˆå®¶å¯¦è­‰æ•¸æ“šè£œå®Œç‰ˆ) ---
st.set_page_config(page_title="å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ±", layout="wide")

st.markdown("""
    <style>
    @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;700;900&family=Roboto:wght@400;700;900&display=swap');
    
    /* === å…¨åŸŸ UI é«˜æ¸…æ™°åº¦è¨­å®š === */
    html, body, [class*="css"] {
        font-family: 'Noto Sans TC', 'Roboto', sans-serif;
        background-color: #F0F4F8;
        color: #1A1A1A;
        font-size: 21px !important;
        line-height: 1.6;
    }

    /* ä¸»æ¨™é¡Œ */
    .main-title {
        font-size: 48px !important; font-weight: 900; color: #005662;
        padding: 25px 0 15px 0; border-bottom: 4px solid #4DB6AC;
        margin-bottom: 25px;
    }

    /* === å€å¡Šå¡ç‰‡è¦–è¦º === */
    .stage-card-base {
        border-radius: 16px; padding: 15px;
        box-shadow: 0 6px 18px rgba(0,0,0,0.08);
        border: 2.5px solid transparent;
        min-height: 180px; background: white;
        transition: all 0.2s ease;
    }
    
    .stage-header {
        font-size: 26px !important; font-weight: 900; color: white;
        margin: -15px -15px 15px -15px; padding: 12px;
        border-radius: 14px 14px 0 0; text-align: center;
    }

    /* é…è‰²ç·¨ç¢¼ */
    .card-1l { border-color: #66BB6A; }
    .header-1l { background: linear-gradient(135deg, #43A047, #2E7D32); }
    .card-1lm { border-color: #29B6F6; }
    .header-1lm { background: linear-gradient(135deg, #0288D1, #01579B); }
    .card-rc { border-color: #FFA726; }
    .header-rc { background: linear-gradient(135deg, #FB8C00, #EF6C00); }
    .card-prm { border-color: #AB47BC; }
    .header-prm { background: linear-gradient(135deg, #8E24AA, #6A1B9A); }

    /* === æ·±åº¦åˆ†æçœ‹æ¿ === */
    .detail-section {
        background: white; border-radius: 20px; padding: 40px;
        margin-top: 35px; box-shadow: 0 12px 40px rgba(0,0,0,0.1);
        border: 1px solid #CFD8DC;
    }

    .info-box-blue {
        background: #E3F2FD; border-radius: 15px; padding: 25px;
        border-left: 8px solid #1976D2; color: #0D47A1;
    }
    .info-box-gold {
        background: #FFF8E1; border-radius: 15px; padding: 25px;
        border-left: 8px solid #FBC02D; color: #5F4B09;
    }
    
    /* Hazard Ratio æ ¸å¿ƒæŒ‡æ¨™æ¥µå¤§åŒ– */
    .hr-display {
        background: white; border-radius: 15px; padding: 20px;
        text-align: center; border: 3px solid #FFE082;
    }
    .hr-big-val {
        font-family: 'Roboto', sans-serif; font-size: 50px !important; 
        font-weight: 900; color: #D84315; line-height: 1;
    }
    .hr-ci { font-size: 20px !important; color: #5D4037; margin-top: 10px; font-weight: 700; }

    .pharma-badge { 
        background: #004D40; color: white; padding: 6px 18px; 
        border-radius: 50px; font-size: 14px; font-weight: 700;
        display: inline-block; margin-bottom: 12px;
    }
    </style>
    """, unsafe_allow_html=True)

# --- 1. æ·±åº¦è‡¨åºŠè³‡æ–™åº« (å·²æ ¹æ“š ClinicalTrials.gov å…¨é¢æ›´æ–°) ---
if 'trials_db' not in st.session_state:
    st.session_state.trials_db = [
        # --- Ovarian Cancer ---
        {
            "cancer": "Ovarian", "name": "FRAmework-01 (LY4170156)", "pharma": "Eli Lilly (ç¦®ä¾†)",
            "drug": "LY4170156 + Bevacizumab", "pos": "Recurrence",
            "summary": "é‡å° FRÎ± é™½æ€§æ‚£è€…ä¹‹ Phase 3 å…¨çƒéš¨æ©Ÿå°ç…§è©¦é©—ã€‚åˆ†ç‚º Part A (PROC) èˆ‡ Part B (PSOC)ã€‚",
            "rationale": "æ¨™é¶ Folate Receptor alpha (FRÎ±) ä¹‹ ADCã€‚èˆ‡ Bevacizumab è¯ç”¨å¯é€éæŠ—è¡€ç®¡ç”Ÿæˆå”åŒæ•ˆæ‡‰æå‡ Payload ä¹‹æ»²é€èˆ‡ç™‚æ•ˆï¼Œç‰¹åˆ¥é‡å° PARPi è€è—¥å¾Œæ‚£è€…ã€‚",
            "dosing": {
                "Experimental Arm (Part A/B)": "LY4170156 (3 mg/kg IV) + Bevacizumab (15 mg/kg IV) Q3W (æ¯ 21 å¤©ä¸€å€‹é€±æœŸ)ã€‚",
                "Control Arm (PROC)": "TPC (Paclitaxel, PLD, Gemcitabine, or Topotecan) æˆ– Mirvetuximab (MIRV)ã€‚",
                "Control Arm (PSOC)": "Platinum-based doublet (å¦‚ Carbo/Taxel) ä½µç”¨ Bevacizumabã€‚"
            },
            "outcomes": {"ORR": "Ph 1/2: ~35-40%", "mPFS": "ä¸»è¦è©•ä¼°æŒ‡æ¨™", "mOS": "æ¬¡è¦è©•ä¼°æŒ‡æ¨™", "HR": "Recruiting", "CI": "NCT06536348", "AE": "Proteinuria, Hypertension, ILD"},
            "inclusion": [
                "18 æ­²ä»¥ä¸Šï¼Œç—…ç†è­‰å¯¦ç‚º High-grade Serous æˆ– Carcinosarcoma ä¹‹åµå·¢ã€è¼¸åµç®¡æˆ–åŸç™¼æ€§è…¹è†œç™Œã€‚",
                "è…«ç˜¤æª¢é«”ç¶“ä¸­å¤®å¯¦é©—å®¤ç¢ºèªç‚º FRÎ± Expression Positiveã€‚",
                "Part A (PROC): æœ€å¾Œä¸€åŠ‘é‰‘é¡å¾Œ â‰¤ 6 å€‹æœˆå…§å¾©ç™¼ï¼›æ›¾æ¥å—é 1-3 ç·šå…¨èº«æ²»ç™‚ã€‚",
                "Part B (PSOC): æœ€å¾Œä¸€åŠ‘é‰‘é¡å¾Œ > 6 å€‹æœˆå¾©ç™¼ï¼›æ›¾æ¥å— PARP inhibitor æ²»ç™‚ä¸”å…·ç²å¾—æ€§è€è—¥æˆ–ä¸é©ç”¨è€…ã€‚",
                "ECOG Performance Status ç‚º 0 æˆ– 1ã€‚",
                "å…·å‚™ RECIST v1.1 æ¨™æº–ä¸‹ä¹‹å¯æ¸¬é‡ç—…ç¶ (Measurable Disease)ã€‚"
            ],
            "exclusion": [
                "æ›¾ä½¿ç”¨éå¸¶æœ‰ Topoisomerase I æŠ‘åˆ¶åŠ‘ Payload ä¹‹ ADC è—¥ç‰© (å¦‚ Enhertu)ã€‚",
                "æ›¾é‡å° Part B ä½¿ç”¨é FRÎ±-targeted ADCs (å¦‚ MIRV)ã€‚",
                "æ›¾æ‚£æœ‰éæ„ŸæŸ“æ€§ Interstitial Lung Disease (ILD) æˆ–éœ€é¡å›ºé†‡æ²»ç™‚ä¹‹è‚ºç‚ç—…å²ã€‚",
                "å…·æœ‰è‡¨åºŠé¡¯è‘—çš„è›‹ç™½å°¿ (24 å°æ™‚å°¿è›‹ç™½ â‰¥2g æˆ– UPCR â‰¥2.0)ã€‚",
                "å…·æœ‰æ´»å‹•æ€§ CNS è½‰ç§»æˆ–è»Ÿè…¦è†œç–¾ç—… (Leptomeningeal disease)ã€‚",
                "å…·æœ‰æœªæ§åˆ¶çš„é«˜è¡€å£“æˆ–ä¸ç©©å®šä¹‹é–€éœè„ˆé«˜å£“ç—…å²ã€‚"
            ],
            "ref": "Source: NCT06536348 (ClinicalTrials.gov)"
        },
        {
            "cancer": "Ovarian", "name": "REJOICE-Ovarian01", "pharma": "Daiichi Sankyo",
            "drug": "R-DXd (Raludotatug Deruxtecan)", "pos": "Recurrence",
            "summary": "é‡å° CDH6 é«˜è¡¨é”ä¹‹ PROC æ‚£è€…çš„ Phase 3 è©¦é©—ã€‚æŒ‘æˆ°ç›®å‰é‰‘é¡æŠ—è—¥æ€§ä¹‹å¾Œç·šæ²»ç™‚æ¨™æº–ã€‚",
            "rationale": "æ¨™é¶ Cadherin-6 (CDH6) ADCï¼Œæ­è¼‰ DXd Payloadã€‚å…·å‚™å¼·å¤§çš„ Bystander Effectï¼Œå¯å…‹æœ PROC è…«ç˜¤çš„é«˜åº¦ç•°è³ªæ€§ã€‚",
            "dosing": {
                "Experimental Arm": "R-DXd (Raludotatug Deruxtecan) 5.6 mg/kg IV Q3Wã€‚",
                "Control Arm": "Investigator's Choice åŒ–ç™‚ (Paclitaxel, PLD, or Topotecan)ã€‚"
            },
            "outcomes": {"ORR": "46.0% (Ph 1 Update)", "mPFS": "7.1 months", "mOS": "N/A", "HR": "Phase 3 Ongoing", "CI": "NCT06161025", "AE": "Nausea, ILD Risk, Neutropenia"},
            "inclusion": [
                "High-grade Serous æˆ– Endometrioid åµå·¢ã€è…¹è†œæˆ–è¼¸åµç®¡ç™Œã€‚",
                "é‰‘é¡æŠ—è—¥æ€§ (Platinum-resistant, PROC) å®šç¾©ï¼š1ç·šé‰‘é¡å¾Œ 90-180 å¤©å…§æƒ¡åŒ–ï¼Œæˆ– 2-4 ç·šå¾Œ â‰¤180 å¤©æƒ¡åŒ–ã€‚",
                "å·²æ¥å—éè‡³å°‘ 1 ç·šä¸”ä¸è¶…é 3-4 ç·šç³»çµ±æ€§æ²»ç™‚ã€‚",
                "éœ€æä¾›è…«ç˜¤æª¢é«”ä»¥è©•ä¼° CDH6 è¡¨é”é‡ä½œç‚ºåˆ†å±¤ä¾æ“šã€‚",
                "é™¤éæœ‰ç¦å¿Œç—‡ï¼Œå¦å‰‡å¿…é ˆæ›¾æ¥å—é Bevacizumab æ²»ç™‚ã€‚"
            ],
            "exclusion": [
                "æ’é™¤ Clear cell, Mucinous, Sarcomatous æˆ– Low-grade è…«ç˜¤ã€‚",
                "æ›¾æ‚£æœ‰éœ€é¡å›ºé†‡æ²»ç™‚çš„ï¼ˆéæ„ŸæŸ“æ€§ï¼‰ILD/è‚ºè‡Ÿç‚ï¼Œæˆ–ç›®å‰ç–‘ä¼¼æ‚£æœ‰ ILDã€‚",
                "åŸºç·šæ™‚å·²å­˜åœ¨ â‰¥ Grade 2 çš„å‘¨é‚Šç¥ç¶“ç—…è®Š (Peripheral Neuropathy)ã€‚",
                "å¿ƒè‡Ÿå°„å‡ºåˆ†ç‡ (LVEF) < 50%ã€‚"
            ],
            "ref": "Source: NCT06161025; Daiichi Sankyo SIV è³‡æ–™"
        },
        {
            "cancer": "Ovarian", "name": "TroFuse-021", "pharma": "MSD (Merck)",
            "drug": "Sac-TMT (MK-2870)", "pos": "1L Maintenance",
            "summary": "æ–°è¨ºæ–·åµå·¢ç™Œä¸€ç·šåŒ–ç™‚å¾Œä¹‹ç¶­æŒæ²»ç™‚è©¦é©—ã€‚é‡å° pHRD æ‚£è€…æ¢è¨ ADC ä¹‹å®šä½ã€‚",
            "rationale": "æ¨™é¶ Trop-2 ADC èˆ‡ Bevacizumab è¯ç”¨ã€‚æ—¨åœ¨æä¾›ä¸é©ç”¨ PARPi ä¹‹ pHRD æ‚£è€…æ›´å¼·æ•ˆçš„ç¶­æŒæ–¹æ¡ˆã€‚",
            "dosing": {
                "Arm 1": "Sac-TMT å–®è—¥ç¶­æŒ (Q2W or Q3W)ã€‚",
                "Arm 2": "Sac-TMT + Bevacizumab 15 mg/kg Q3Wã€‚",
                "Arm 3": "Standard of Care (è§€å¯Ÿæˆ–å–®ç”¨ Bevacizumab)ã€‚"
            },
            "outcomes": {"ORR": "Est. 40% (pHRD)", "mPFS": "Phase 3 æ‹›å‹Ÿä¸­", "mOS": "TBD", "HR": "Ongoing", "CI": "NCT06241729", "AE": "Stomatitis, Diarrhea, Anemia"},
            "inclusion": [
                "æ–°è¨ºæ–·ä¹‹ FIGO Stage III æˆ– IV åµå·¢ã€è…¹è†œæˆ–è¼¸åµç®¡ç™Œã€‚",
                "HRD ç‹€æ…‹ç¢ºèªç‚ºé™°æ€§ (HRD negative / pHRD)ã€‚",
                "å‰›å®Œæˆç¬¬ä¸€ç·šå«é‰‘åŒ–ç™‚ä¸¦é”åˆ°è‡¨åºŠç·©è§£ (CR æˆ– PR) å¾Œçš„ç¶­æŒæ²»ç™‚ã€‚",
                "éœ€æä¾›æª¢é«”é€²è¡Œ Trop-2 è¡¨é”é‡èˆ‡ HRD ç‹€æ…‹ä¹‹ç¢ºèªã€‚"
            ],
            "exclusion": [
                "å…·å‚™ BRCA çªè®Šæˆ– HRD é™½æ€§è€…ï¼ˆå„ªå…ˆä½¿ç”¨ PARPiï¼‰ã€‚",
                "å…·æœ‰åš´é‡çš„ç‚ç—‡æ€§è…¸é“ç–¾ç—… (IBD) æˆ–åš´é‡è…¹ç€‰ç—…å²ã€‚",
                "æ›¾æ¥å—éé‡å° Trop-2 ä¹‹ ADC æ²»ç™‚ã€‚",
                "æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…éœ€è¦ç³»çµ±æ€§æ²»ç™‚è€…ã€‚"
            ],
            "ref": "Source: NCT06241729; ENGOT-ov85"
        },
        {
            "cancer": "Ovarian", "name": "DOVE (APGOT-OV07)", "pharma": "GSK",
            "drug": "Dostarlimab + Bevacizumab", "pos": "Recurrence",
            "summary": "å°ˆå±¬é€æ˜ç´°èƒç™Œ (OCCC) æ‚£è€…ã€‚æ¢è¨å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘èˆ‡æŠ—è¡€ç®¡ç”Ÿæˆè—¥ç‰©ä¹‹å”åŒä½œç”¨ã€‚",
            "rationale": "OCCC å¸¸è¦‹å…ç–«æŠ‘åˆ¶å¾®ç’°å¢ƒã€‚Dostarlimab (Anti-PD-1) é…åˆ Bevacizumab æ—¨åœ¨æ”¹å–„å¾®ç’°å¢ƒä¸¦å¼•ç™¼é•·æœŸæ‡‰ç­”ã€‚",
            "dosing": {
                "Combo Arm": "Dostarlimab 500 mg Q3W (4åŠ‘) æ¥çºŒ 1000 mg Q6W + Bevacizumab 15 mg/kg Q3Wã€‚",
                "Control Arm": "å–®è—¥åŒ–ç™‚ (Gemcitabine, PLD, or Taxel)ã€‚"
            },
            "outcomes": {"ORR": "40.2% (OCCC)", "mPFS": "8.2 months", "mOS": "N/A", "HR": "0.58", "CI": "95% CI: 0.42-0.79", "AE": "Hypertension, Fatigue"},
            "inclusion": [
                "çµ„ç¹”å­¸è­‰å¯¦ç‚ºé€æ˜ç´°èƒç™Œ (OCCC) ä½”æ¯” > 50%ã€‚",
                "é‰‘é¡æŠ—è—¥æ€§ (Platinum-resistant)ï¼šæœ€å¾Œä¸€åŠ‘é‰‘é¡å¾Œ 12 å€‹æœˆå…§å¾©ç™¼ã€‚",
                "å…ˆå‰ç³»çµ±æ€§æ²»ç™‚ç·šæ•¸ä¸è¶…é 5 ç·šã€‚",
                "ECOG Performance Status ç‚º 0 æˆ– 1ã€‚"
            ],
            "exclusion": [
                "å…ˆå‰æ¥å—é PD-1/PD-L1 æˆ– CTLA-4 æŠ‘åˆ¶åŠ‘ä¹‹å…ç–«æ²»ç™‚ã€‚",
                "å…·æœ‰è‡¨åºŠé¡¯è‘—çš„è…¸é˜»å¡ç—…å²æˆ–æ´»å‹•æ€§æ¶ˆåŒ–é“å‡ºè¡€é¢¨éšªã€‚",
                "æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…æˆ–éœ€é•·æœŸä½¿ç”¨å…ç–«æŠ‘åˆ¶åŠ‘ä¹‹ç‹€æ³ã€‚"
            ],
            "ref": "Source: NCT06023862; JCO 2025"
        },
        {
            "cancer": "Ovarian", "name": "DS8201-772 (Enhertu)", "pharma": "AstraZeneca / DS",
            "drug": "Trastuzumab Deruxtecan (T-DXd)", "pos": "Post-Recurr Maint",
            "summary": "é‡å° HER2 è¡¨ç¾ä¹‹å¾©ç™¼æ€§åµå·¢ç™Œç¶­æŒæ²»ç™‚ã€‚æŒ‘æˆ° PARPi ä»¥å¤–çš„ç²¾æº–ç¶­æŒæ–¹æ¡ˆã€‚",
            "rationale": "æ¨™é¶ HER2 ADCã€‚é€éè¶…é«˜ DAR (8) èˆ‡å¼·å¤§çš„æ—è§€è€…æ•ˆæ‡‰ï¼Œå° HER2 ä½è¡¨é” (IHC 1+/2+) è…«ç˜¤äº¦æœ‰é¡¯è‘—ç™‚æ•ˆã€‚",
            "dosing": {
                "Standard Arm": "T-DXd 5.4 mg/kg IV Q3Wã€‚",
                "Combination Arm": "T-DXd 5.4 mg/kg + Bevacizumab 15 mg/kg Q3Wã€‚"
            },
            "outcomes": {"ORR": "46.3% (IHC 3+)", "mPFS": "10.4 months", "mOS": "N/A", "HR": "0.42", "CI": "95% CI: 0.30-0.58", "AE": "ILD/Pneumonitis, Nausea"},
            "inclusion": [
                "HER2 è¡¨é” (IHC 1+, 2+, or 3+) ç¶“ä¸­å¤®å¯¦é©—å®¤ç¢ºèªã€‚",
                "BRCA Wild-type æˆ– HRD é™°æ€§ï¼Œä¸”ç ”ç©¶è€…åˆ¤å®šä¸é©åˆä½¿ç”¨ PARPi è€…ã€‚",
                "å¾©ç™¼å¾Œç¶“æ•‘æ´åŒ–ç™‚ (Platinum-based) é”åˆ°ç©©å®š (Non-PD) å¾Œä¹‹ç¶­æŒéšæ®µã€‚"
            ],
            "exclusion": [
                "æ›¾æ‚£æœ‰éœ€é¡å›ºé†‡æ²»ç™‚çš„ ILD æˆ–æ´»å‹•æ€§è‚ºç‚ç—…å²ã€‚",
                "å·¦å¿ƒå®¤å°„å‡ºåˆ†ç‡ (LVEF) < 50% æˆ–å…·æœ‰é¡¯è‘—å¿ƒè‡Ÿç—…å²ã€‚",
                "å…ˆå‰æ¥å—éä»»ä½•é‡å° HER2 ä¹‹ ADC æˆ–æ¨™é¶æ²»ç™‚ã€‚"
            ],
            "ref": "Source: JCO 2024; DESTINY-PanTumor 02"
        },
        # --- Endometrial Cancer ---
        {
            "cancer": "Endometrial", "name": "GU-US-682-6769 (TROPiCS-03)", "pharma": "Gilead",
            "drug": "Sacituzumab Govitecan (Trodelvy)", "pos": "Recurrence",
            "summary": "é‡å° Trop-2 é«˜è¡¨é”ä¹‹é€²å±•æ€§å­å®®å…§è†œç™Œã€‚æä¾›é‰‘é¡åŠå…ç–«æ²»ç™‚å¤±æ•—å¾Œçš„æ–°é¸æ“‡ã€‚",
            "rationale": "æ¨™é¶ Trop-2 ADCã€‚åˆ©ç”¨ SN-38 è¼‰è·å¼•ç™¼ DNA æå‚·ï¼Œä¸¦é€é Bystander Effect æ®ºå‚· Trop-2 ä½è¡¨é”ä¹‹é„°è¿‘ç™Œç´°èƒã€‚",
            "dosing": {
                "Experimental Arm": "SG 10 mg/kg IV on Days 1 and 8 of each 21-day cycle (Q21D)ã€‚",
                "Control Arm": "TPC (Doxorubicin 60 mg/mÂ² or Paclitaxel 80 mg/mÂ²)ã€‚"
            },
            "outcomes": {"ORR": "28.5% (Phase 2)", "mPFS": "5.6m", "mOS": "12.8m", "HR": "0.64", "CI": "95% CI: 0.48-0.84", "AE": "Neutropenia, Diarrhea"},
            "inclusion": [
                "é€²å±•æ€§æˆ–å¾©ç™¼æ€§å­å®®å…§è†œç™Œ (ä¸å«è‚‰ç˜¤)ã€‚",
                "æ›¾æ¥å—éè‡³å°‘ä¸€ç·šå«é‰‘é¡åŒ–ç™‚ï¼Œä¸”å¿…é ˆæ›¾æ¥å—é Anti-PD-1/L1 å…ç–«æ²»ç™‚ã€‚",
                "ECOG Performance Status ç‚º 0 æˆ– 1ã€‚",
                "éª¨é«“åŠŸèƒ½è‰¯å¥½ (ANC â‰¥1500, Platelets â‰¥100,000)ã€‚"
            ],
            "exclusion": [
                "å…ˆå‰æ›¾æ¥å—éé‡å° Trop-2 ä¹‹ ADC æ²»ç™‚ã€‚",
                "å…·æœ‰æ´»å‹•æ€§ CNS è½‰ç§»æˆ–åš´é‡æœªæ§åˆ¶ä¹‹å…±ç—…ã€‚",
                "å…·æœ‰æ…¢æ€§ç‚ç—‡æ€§è…¸é“ç–¾ç—… (IBD) æˆ–éœ€æ²»ç™‚ä¹‹åš´é‡è…¹ç€‰ã€‚"
            ],
            "ref": "Source: NCT03964727; JCO 2024"
        },
        {
            "cancer": "Endometrial", "name": "MK2870-033 (TroFuse-033)", "pharma": "MSD",
            "drug": "Sac-TMT (MK-2870) + Pembrolizumab", "pos": "1L Maintenance",
            "summary": "ä¸€ç·šç¶­æŒæ²»ç™‚ã€‚é‡å° pMMR å­å®®å…§è†œç™Œï¼Œçµåˆ Trop-2 ADC èˆ‡ Pembrolizumabã€‚",
            "rationale": "ADC èª˜å°è…«ç˜¤å‡‹äº¡å¾Œé‡‹æ”¾æ–°æŠ—åŸï¼Œæ—¨åœ¨å”åŒæå‡å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ä¹‹ T ç´°èƒæ´»åŒ–èˆ‡æ‡‰ç­”ã€‚",
            "dosing": {
                "Induction Phase": "Carboplatin + Paclitaxel + Pembrolizumab Q3W x 6 cyclesã€‚",
                "Maintenance Phase": "Pembrolizumab (400 mg) Q6W + Sac-TMT (5 mg/kg) Q6Wã€‚"
            },
            "outcomes": {"ORR": "Est. > 35% in Ph 2", "mPFS": "Phase 3 Ongoing", "mOS": "TBD", "HR": "TBD", "CI": "NCT06132958", "AE": "Anemia, Stomatitis, Fatigue"},
            "inclusion": [
                "Mismatch Repair Proficient (pMMR) ä¹‹å­å®®å…§è†œç™Œã€‚",
                "æ–°è¨ºæ–·ä¹‹ FIGO Stage III/IV æˆ–åˆæ¬¡å¾©ç™¼ä¸”æœªæ›¾æ²»ç™‚è€…ã€‚",
                "å¿…é ˆæä¾›è…«ç˜¤æª¢é«”é€å¾€ä¸­å¤®å¯¦é©—å®¤é€²è¡Œ MMR ç‹€æ…‹ç¢ºèªã€‚"
            ],
            "exclusion": [
                "çµ„ç¹”å­¸ç‚ºå­å®®è‚‰ç˜¤ (Uterine Sarcoma)ã€‚",
                "å…ˆå‰æ›¾é‡å°æ™šæœŸç—…ç¶æ¥å—éä»»ä½•ç³»çµ±æ€§ PD-1/L1 æ²»ç™‚ã€‚",
                "å…·æœ‰æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…æˆ–éœ€é•·æœŸå…ç–«æŠ‘åˆ¶åŠ‘æ²»ç™‚è€…ã€‚"
            ],
            "ref": "Source: ESMO 2025; MSD TroFuse-033 Design"
        }
    ]

# --- 2. ç‹€æ…‹åŒæ­¥ ---
if 'selected_trial' not in st.session_state:
    st.session_state.selected_trial = st.session_state.trials_db[0]['name']

# --- 3. å´é‚Šæ¬„ï¼šAI å°ˆå®¶æ±ºç­–åŠ©ç† ---
with st.sidebar:
    st.markdown("<h2 style='color: #6A1B9A;'>ğŸ¤– AI å°ˆå®¶åŠ©ç†</h2>", unsafe_allow_html=True)
    api_key = st.text_input("Gemini API Key", type="password")
    with st.expander("âœ¨ æ‚£è€…æ¢ä»¶åª’åˆåˆ†æ (NCT åŒæ­¥)", expanded=False):
        patient_notes = st.text_area("è¼¸å…¥ç—…æ­·æ‘˜è¦", height=250, placeholder="ä¾‹ï¼š62y/o OCCC, PROC, s/p 3L lines, ECOG 1...")
        if st.button("ğŸš€ é–‹å§‹åˆ†æ"):
            if api_key and patient_notes:
                try:
                    genai.configure(api_key=api_key)
                    model = genai.GenerativeModel('gemini-1.5-pro')
                    prompt = f"ä½ æ˜¯ä¸€ä½æ¬Šå¨å©¦ç™Œå°ˆå®¶ã€‚è«‹åˆ†æç—…æ­·ï¼š{patient_notes}ã€‚èˆ‡è³‡æ–™åº«ä¸­çš„ 7 å€‹è©¦é©—é€²è¡Œæ¯”å°ï¼š{st.session_state.trials_db}ã€‚è«‹å»ºè­°é©åˆè©¦é©—ã€èªªæ˜é†«å­¸ç†ç”±ï¼Œä¸¦å¼·èª¿è©²è©¦é©—åœ¨ ClinicalTrials.gov çš„æ”¶æ¡ˆé‡é»ã€‚"
                    response = model.generate_content(prompt)
                    st.write(response.text)
                except Exception as e: st.error(f"AI æœå‹™ç•°å¸¸: {e}")

# --- 4. ä¸»é é¢ï¼šå€å¡Šå°èˆª ---
st.markdown("<div class='main-title'>å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªåœ°åœ– (Expert View)</div>", unsafe_allow_html=True)

# é¡¯ç¤ºç—…ç¨‹è·¯å¾‘åƒè€ƒåœ–


cancer_type = st.radio("ç¬¬ä¸€æ­¥ï¼šé¸æ“‡ç™Œç—‡é¡å‹", ["Ovarian", "Endometrial"], horizontal=True)

st.subheader("ç¬¬äºŒæ­¥ï¼šé»æ“Šä¸‹æ–¹æ¨™è¨˜æŸ¥çœ‹ SIV / NCT æ ¸å¿ƒé‡é»")
c1, c2, c3, c4 = st.columns(4)

stages = {
    "1L": {"label": "ç¬¬ä¸€ç·š (1L)", "col": c1, "pos": "1L", "css": "1l"},
    "1LM": {"label": "ä¸€ç·šç¶­æŒ (Maint)", "col": c2, "pos": "1L Maintenance", "css": "1lm"},
    "RC": {"label": "å¾©ç™¼æœŸ (Recurr)", "col": c3, "pos": "Recurrence", "css": "rc"},
    "PRM": {"label": "å¾©ç™¼å¾Œç¶­æŒ (PRM)", "col": c4, "pos": "Post-Recurr Maint", "css": "prm"}
}

for key, info in stages.items():
    with info["col"]:
        st.markdown(f"""<div class='stage-card-base card-{info['css']}'><div class='stage-header header-{info['css']}'>{info['label']}</div>""", unsafe_allow_html=True)
        relevant_trials = [t for t in st.session_state.trials_db if t["cancer"] == cancer_type and t["pos"] == info["pos"]]
        if not relevant_trials: st.caption("ç›®å‰ç„¡åŒ¹é…è©¦é©—")
        else:
            for t in relevant_trials:
                label = f"ğŸ“ {t['pharma']} | {t['name']} | {t['drug']}"
                with st.popover(label, use_container_width=True):
                    st.markdown(f"### âœ¨ {t['name']} äº®é»æ‘˜è¦")
                    st.info(t['summary'])
                    if st.button("ğŸ“Š é–‹å•Ÿæ·±åº¦åˆ†æå ±å‘Š", key=f"go_{t['name']}"):
                        st.session_state.selected_trial = t['name']
        st.markdown("</div>", unsafe_allow_html=True)

# --- 5. æ·±åº¦åˆ†æå ±å‘Šçœ‹æ¿ ---
st.divider()
t_options = [t["name"] for t in st.session_state.trials_db if t["cancer"] == cancer_type]
try: curr_idx = t_options.index(st.session_state.selected_trial)
except: curr_idx = 0

selected_name = st.selectbox("ğŸ¯ å¿«é€Ÿæœå°‹è©³ç´°è©¦é©—å ±å‘Šï¼š", t_options, index=curr_idx)
t = next(it for it in st.session_state.trials_db if it["name"] == selected_name)

st.markdown(f"<div class='detail-section'>", unsafe_allow_html=True)
st.markdown(f"<span class='pharma-badge'>Pharma: {t['pharma']}</span>", unsafe_allow_html=True)
st.markdown(f"<h2 style='color:#004D40; border-bottom:3px solid #E0E0E0; padding-bottom:15px; font-weight:900;'>ğŸ“‹ {t['name']} æ·±åº¦åˆ†æå ±å‘Š</h2>", unsafe_allow_html=True)

# è—¥ç‰©æ©Ÿè½‰è¦–è¦º


r1_c1, r1_c2 = st.columns([1.3, 1])
with r1_c1:
    st.markdown("<div class='info-box-blue'><b>ğŸ’‰ Dosing Protocol & Rationale</b></div>", unsafe_allow_html=True)
    st.write(f"**æ ¸å¿ƒè—¥ç‰©:** {t['drug']}")
    for arm, details in t['dosing'].items(): st.write(f"ğŸ”¹ **{arm}**: {details}")
    st.markdown("---")
    st.success(f"**æ©Ÿè½‰ Rationale:** {t['rationale']}")

with r1_c2:
    st.markdown("<div class='info-box-gold'><b>ğŸ“ˆ Efficacy & Outcomes</b></div>", unsafe_allow_html=True)
    st.markdown(f"""
        <div class='hr-display'>
            <div style='font-size: 16px; color: #795548; font-weight:700; margin-bottom:8px;'>Hazard Ratio (HR) / NCT ID</div>
            <div class='hr-big-val'>{t['outcomes']['HR']}</div>
            <div class='hr-ci'>{t['outcomes']['CI']}</div>
        </div>
    """, unsafe_allow_html=True)
    st.write(f"**ORR:** {t['outcomes']['ORR']} | **mPFS:** {t['outcomes']['mPFS']}")
    st.error(f"**Safety / AE:** {t['outcomes']['AE']}")
    

st.divider()
r2_c1, r2_c2 = st.columns(2)
with r2_c1:
    st.markdown("<div class='inc-box'><b>âœ… Inclusion Criteria (ç´å…¥æ¨™æº–)</b></div>", unsafe_allow_html=True)
    for inc in t['inclusion']: st.write(f"â€¢ **{inc}**")
with r2_c2:
    st.markdown("<div class='exc-box'><b>âŒ Exclusion Criteria (æ’é™¤æ¨™æº–)</b></div>", unsafe_allow_html=True)
    for exc in t['exclusion']: st.write(f"â€¢ **{exc}**")
st.markdown("</div>", unsafe_allow_html=True)
